FDA Brief

Warning letters Drugs

FDA warning letter to

Cannafyl

High riskIssued Mar 1, 2021Posted Mar 9, 2021Center for Drug Evaluation and Research

Cannafyl sold CBD drops, salve and pet drops as unapproved drugs with claims to treat COVID-19, cancer and other diseases.

What happened

FDA reviewed Cannafyl's website in November 2020 and its Facebook, Twitter and Instagram pages. FDA found the company took orders for CBD products for humans and pets and promoted them with claims to mitigate, prevent, treat, diagnose or cure COVID-19 and other diseases such as cancer, epilepsy and opioid withdrawal. The letter says these claims make the products unapproved new drugs and an unapproved new animal drug.

What FDA found

  1. CBD products for humans are unapproved new drugs because they are intended to treat diseases such as COVID-19, cancer and epilepsy without FDA approval.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  2. The human CBD products are misbranded, meaning their labeling does not give adequate directions for safe use.

    FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1)
  3. The CBD drops are marketed as dietary supplements, but FDA says CBD is excluded from that category and sublingual drops are not intended for ingestion.

    FD&C Act sections 201(ff)(3)(B)(i)-(ii) and 201(ff)(2)(A)(i), 21 U.S.C. 321(ff)(3)(B)(i)-(ii) and 321(ff)(2)(A)(i)
  4. Pet CBD Drops is an unapproved new animal drug that FDA considers unsafe and therefore adulterated (illegal).

    FD&C Act sections 512(a) and 501(a)(5), 21 U.S.C. 360b(a) and 351(a)(5)

What FDA wants

FDA tells Cannafyl to immediately stop selling unapproved products claimed to mitigate, prevent, treat, diagnose or cure COVID-19. The company must respond in writing within 15 working days with the specific steps taken and documentation, or explain why it cannot complete them and when it will.

Who should pay attention

  • CBD brands and retailers making disease-treatment claims
  • pet supplement companies making drug claims
  • regulatory teams reviewing website and social media claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk